Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Abstract Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study. To examine this hypothesis clinically, we compared the glucose‐lowering effects of...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Yumie Takeshita, Yuki Kita, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Chisato Teramura, Yasufumi Enyama, Toshinari Takamura, the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2022-06-01
Serier:	Journal of Diabetes Investigation
Fag:	Glucagon‐like peptide‐1 receptor agonists Glucose toxicity Insulin–glucagon‐like peptide‐1 receptor agonist relay regimen
Online adgang:	https://doi.org/10.1111/jdi.13749
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!